Akero Therapeutics, Inc. Stock
Stocks
AKRO
US00973Y1082
Biotechnology & Medical Research
Last Transcript: Akero Therapeutics, Inc.
| 1 day | +0.18% |
| 1 year | 53.4 |  | 54.82 |
| 3 years | 11.25 | | 58.4 |
| 5 years | 7.52 | | 58.4 |
| 10 years | 7.52 | | 58.4 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jonathan Young
CEO | Chief Executive Officer | 56 | 2017-03-31 |
Daniel Bohsen
PSD | President | - | 2025-12-08 |
| Chief Tech/Sci/R&D Officer | - | 2020-11-30 |
| Director | Title | Age | Since |
|---|---|---|---|
Daniel Bohsen
BRD | Director/Board Member | - | 2025-12-08 |
John Kuckelman
BRD | Director/Board Member | - | 2025-12-08 |
Steve Benz
BRD | Director/Board Member | - | 2025-12-08 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | Importance |
|---|---|---|---|---|---|---|
| 12/9/25 | Issuer sale | Founder | 688,163 | 0.8360% | ||
| 12/9/25 | Issuer sale | Director | 401,762 | 0.4881% | ||
| 12/9/25 | Issuer sale | Director | 91,398 | 0.1110% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +0.18% | -.--% | - | - | 4.5B | |
| +0.79% | -6.46% | +52.86% | +71.34% | 65.83B | |
| +1.92% | +8.89% | +12.90% | +82.75% | 51.87B | |
| +6.91% | +6.41% | +9.61% | +73.07% | 51.2B | |
| +0.74% | +2.15% | +30.95% | +43.43% | 43.76B | |
| +3.87% | +9.73% | +21.52% | +142.33% | 42.09B | |
| +7.91% | +1.34% | +263.31% | +577.76% | 39.04B | |
| -0.40% | +9.42% | +18.44% | +59.06% | 34B | |
| +3.84% | -4.94% | +42.35% | +8.92% | 25.2B | |
| +2.36% | +4.62% | +24.20% | +31.02% | 22.8B | |
| Average | +2.81% | +0.51% | +52.90% | +121.07% | 41.76B | |
| Weighted average by Cap. | +3.02% | +0.62% | +51.69% | +122.72% |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
